In previous papers [1] [2] [3] we reported the syntheses, pharmacological evaluation and classification of series of aromatic amides of N-alkylated and N-acylated amino acids, according to the Anticonvulsant Screening Project (ASP). All of them, with one exception, were derivatives of linear amino acids. This exception was (R)-acetylproline benzylamide ((R)-Ac-Pro-BZA), which has been demonstrated as effective in mice against the maximal electroshock seizure (MES) ED 50 ϭ 67.4 mg/kg body weight (b.w.), against the subcutaneous pentylenetetrazol (sc PTZ) ED 50 ϭ183.8 mg/kg b.w., the rotarod neurotoxicity (Tox) TD 50 ϭ303.8 mg/kg b.w. and the protective index (PI), (MES)ϭ4.5.
though its function is not yet clear. It has been reported that Tau and growth factors protect the brain against excitotoxicity. 5) It is supposed that Tau acts on excitatory amino acid (EAA) receptors and therefore it would be worth to obtain and the pharmacological properties of taurine benzylamide, a potential EAA receptor antagonist with anticonvulsant activity.
Chemistry Syntheses were carried out as follows: General methods of synthesis, as well as untypical proceedings are given in the Experimental part. All the products were purified by crystallization or column chromatography (CC) and characterized by TLC, HPLC, 1 H-NMR, elemental analysis, and if necessary, by optical rotation determination. Physical and analytical data of the synthesized compounds are given in Tables 1 and 2 Table 4 .
Experimental
Elemental analyses were performed on a Perkin-Elmer Microanalyzer. Melting points were determined in a Böetius apparatus.
1 H-NMR spectra were recorded on a Varian, Unity 200 or 500 spectrometer. Chemical shifts were measured as d units (ppm) relative to tetramethylsilane. TLC was carried out on a 0.25 mm thickness silica gel plates (Merck Kieselgel 60 F-254). The spots were visualized with 0.3% ninhydrin in EtOH/AcOH (97 : 3) and 7% phosphomolybdic acid in EtOH. HPLC was performed on a Techma-Robot Type 302 apparatus equipped with a UV detector LCD 2040 (Laboratorni Pristroje, Praha) and a computer registrator/recorder CHROMA (POLLAB Warsaw). The peaks were recorded at 210 nm, CC was carried out under gravity on silica gel (Merck, grade 230 to 400 mesh). The solvent systems used in TLC and CC were: CHCl 3 /MeOH (50 : 50) (A), HPLC purity of compounds 2, 4, 5, 7, 8, 10, 11, 14-16 is not less than 99%. The elemental analyses were within Ϯ0.4% of the theoretical value. a) Class Iϭanticonvulsant activity at dose of 100 mg/kg or less, class IIϭanticonvulsant activity at a dose greater than 100 mg/kg, class IIIϭno anticonvulsant activity at a dose up to an including 300 mg/kg. b) Hydrophobicity of the compounds expressed as log P value calculated by a computer method (HyperChem (Hypercube, Inc.), ChemPlus, QSAR Properties Program). 7) using Bocazide and was removed with HCl/dioxane in the typical manner.
Acetylation (2S,4R)-Ac-Pro(4-OH)-BZA (4) (9) were obtained by the acetylation of (RS)-ϽGlu-OH and (RS)-ϽGlu-OBzl with boiling acetic anhydride for 15 min. Then the solution was concentrated in vacuo and several times concentrated with MeOH until the acetic acid smell disappeared and then it was dried in vacuo over solid NaOH.
Cbz-Tau-OH This compound was obtained by the modified Bergmann et al. method. 8) Tau-OH was dissolved in 4 M NaOH. The solution was cooled to 0°C and stirred with an excess of Cbz-Cl chloride for 2 h and at room temperature overnight. The mixture was then extracted 3 times with ethyl ether. The alkaline solution was acidified to pH 6.0 and concentrated. The residue was extracted with dimethylformamide (DMF), the solution was filtered and concentrated in vacuo to a small volume. A four times volume of ethyl ether was added into this solution and the mixture was left for 12 h in refrigerator. The obtained crystals were filtered, dissolved in dry DMF, treated with ethyl ether and again left to crystallize. Crystals of Cbz-TauONa were dried in vacuo, dissolved in H 2 O and filtered on a column with Amberlite IRC 50 in the H ϩ form. The filtrate was concentrated in vacuo, then concentrated several times with MeOH and benzene and dried in vacuo. The obtained raw product was used without further purification.
Cbz-Tau-Cl Raw Cbz-Tau-OH was dissolved in dry benzene and an excess of thionyl chloride was added. The mixture was stirred overnight at room temperature and then boiled for 1 h. This solution was concentrated in vacuo and the oily residue was dissolved in dry benzene. The solution was filtered, concentrated in vacuo, treated with hexane and left for several hours in a refrigerator. The obtained crystalline raw material was dried in vacuo.
Cbz-Tau-BZA Raw Cbz-Tau-Cl (0.97 g, 3.4 mmol) was dissolved in ethyl ether (20 ml) and benzylamine (0.72 g, 6.8 mmol) in ethyl ether was added. This solution was stirred at room temperature for 6 h, then filtered and concentrated in vacuo. The oily residue was dissolved in ethyl ether (20 ml) and washed with 20 ml portions of 2 M HCl, saturated NaHCO 3 solution and saturated NaCl solution. The ethereal solution was dried with anhydrous MgSO 4 and concentrated in vacuo. The obtained product was purified by CC. Physicochemical data are given in Tables 1 and 2 .
N-Methylation (R)-Pro-OH and HClϫ(2S,4R)-Pro-(4-OH)-BZA were N-methylated using formaldehyde solution and catalytical hydrogenation according to the method of Moore.
9)
(RS)-ϽGlu-OBzl Benzyl ester group was introduced by the procedure of Wang et al. 10) Physicochemical data are given in Tables 1 and 2 . Preparation of Benzylamides A BZA group was introduced by the following procedure: An amino acid or its derivative with a free carboxyl function (10 mmol) was dissolved in dry tetrahydrofuran (THF) or a mixture of THF/DMF (40 ml). Then N-methylmorpholine (NMM) (10 mmol) was added and the mixture was stirred under nitrogen and chilled to Ϫ15°C. Isobutyl chloroformate (10 mmol) in THF (4 ml) was added dropwise to keep the temperature below Ϫ15°C. BZA (10 mmol) in THF (4 ml) was added in small portions and the reaction mixture was stirred at Ϫ15°C for 30 min and at room temperature for 1 h. The solution was concentrated in vacuo and the residue was dissolved in EtOAc (20 ml). This solution was washed with 20 ml portions of 1 M HCl, saturated NaHCO 3 solution and saturated NaCl solution, then dried with anhydrous MgSO 4 , filtered and concentrated in vacuo. The residue was crystallized with EtOAc/hexane.
Pharmacology. Preliminary Evaluation of Anticonvulsant Activity and Neurotoxicity in Phase I Identification (ASP) The synthesized compounds 2, 4, 5, 7, 9-11, 14-16 were tested in mice after ip administration. Tests of MES, sc PTZ and Tox were performed according to the method given by Krall et al. 11) as described in the previous paper.
1 ) The results qualifying the compounds into class I, II or III of ASP are given in Table 1 .
Quantitative Assessment of Anticonvulsant Activity in Phase VIb Quantification (ASP) Three compounds (7, 11, 15) were examined in rats after oral administration using the method of Krall et al. 11) described in the previous paper.
1 ) The results are given in Table 3 .
Determination of Anticonvulsant Activity of Compound 15
This compound was administered ip in adult male Swiss mice. Pilocarpine and strychnine were injected ip. Bicuculline and PTZ were administred sc. Kainic acid, NMDA and AMPA were applied intracerebroventricularly (icv). All convulsants were administered at the dose inducing seizures in 97% of tested animals. A detailed description of the methods was published previously. [12] [13] [14] The results are given in Table 4 .
